Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer

Vivek Roy, Edith A. Perez

Research output: Contribution to journalComment/debatepeer-review

Abstract

In summary, on the basis of available data, TAC can be considered as an acceptable option for patients with resected node-positive breast cancer and a step in the ongoing evolution of adjuvant chemotherapy regimens. The significantly increased toxicity of the regimen cannot be overlooked and the oncologists should carefully evaluate the efficacy/toxicity ratio of the regimen on an individualised basis; including the addition of prophylactic growth factor support. Whether TAC will prove superior to the other contemporary regimens, such as dose-dense AC → T, must await the results of ongoing clinical trials. Patients should be encouraged to enroll in these and other clinical trials whenever possible.

Original languageEnglish (US)
Pages (from-to)55-58
Number of pages4
JournalCancer Treatment Reviews
Volume32
Issue number1
DOIs
StatePublished - Feb 2006

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer'. Together they form a unique fingerprint.

Cite this